We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+42.12%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$9.76B
AUM Growth
+$1.65B
(+20%)
Cap. Flow
-$15.2M
Cap. Flow
% of AUM
-0.16%
Top 10 Holdings %
Top 10 Hldgs %
65.63%
Holding
88
New
21
Increased
14
Reduced
8
Closed
17
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$114M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$105M |
| 3 |
Rezolute
RZLT
|
+$72M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$69.6M |
| 5 |
EVMN
Evommune Inc
EVMN
|
+$65M |
Top Sells
| 1 |
ETNB
89bio
ETNB
|
+$292M |
| 2 |
ACLX
Arcellx
ACLX
|
+$141M |
| 3 |
Vaxcyte
PCVX
|
+$55.5M |
| 4 |
BLTE
Belite Bio
BLTE
|
+$52.4M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$48.7M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$17.4B
| $2.19B | 22.46% |
10,281,496
| – | – |
|
|
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
| $743M | 7.62% |
3,365,523
| – | – |
|
|
3
Rhythm Pharmaceuticals
RYTM
$7.54B
| $714M | 7.31% |
6,666,837
+985,478
| +17% | +$105M |
|
|
RNAM
4
DELISTED
Avidity Biosciences
RNAM
| $623M | 6.39% |
8,641,031
| – | – |
|
|
5
Vaxcyte
PCVX
$8.12B
| $495M | 5.07% |
10,724,599
-1,241,392
| -10% | -$55.5M |
|
|
SION
6
Sionna Therapeutics
SION
$1.92B
| $407M | 4.17% |
9,905,045
-540,277
| -5% | -$20.5M |
|
7
NewAmsterdam Pharma
NAMS
$3.89B
| $335M | 3.43% |
9,550,191
-588,747
| -6% | -$21.4M |
|
8
Tyra Biosciences
TYRA
$1.96B
| $321M | 3.29% |
12,198,625
| – | – |
|
9
Wave Life Sciences
WVE
$1.18B
| $309M | 3.17% |
18,203,009
+1,000
| +0% | +$10.2K |
|
10
Mineralys Therapeutics
MLYS
$2.4B
| $266M | 2.72% |
7,323,750
| – | – |
|
11
Edgewise Therapeutics
EWTX
$4.27B
| $259M | 2.65% |
10,428,437
| – | – |
|
|
SEPN
12
Septerna Inc
SEPN
$1.56B
| $195M | 2% |
6,995,858
| – | – |
|
13
Nuvalent
NUVL
$9.81B
| $189M | 1.94% |
1,880,057
+633,601
| +51% | +$62.5M |
|
14
Disc Medicine
IRON
$2.87B
| $157M | 1.61% |
1,976,132
+399,026
| +25% | +$33.7M |
|
15
Janux Therapeutics
JANX
$962M
| $154M | 1.58% |
11,189,693
| – | – |
|
16
PepGen
PEPG
$169M
| $131M | 1.34% |
20,064,545
| – | – |
|
17
Taysha Gene Therapies
TSHA
$1.64B
| $130M | 1.33% |
23,555,648
| – | – |
|
18
ARS Pharmaceuticals
SPRY
$756M
| $127M | 1.3% |
10,860,977
| – | – |
|
|
19
BioCryst Pharmaceuticals
BCRX
$2.48B
| $123M | 1.26% |
+15,827,186
| New | +$114M |
|
|
BCAX
20
Bicara Therapeutics
BCAX
$1.85B
| $117M | 1.2% |
6,955,993
| – | – |
|
|
21
Praxis Precision Medicines
PRAX
$9.14B
| $110M | 1.13% |
+373,787
| New | +$69.6M |
|
22
GH Research
GHRS
$1.84B
| $97.5M | 1% |
7,676,697
| – | – |
|
23
Geron
GERN
$885M
| $84.2M | 0.86% |
63,771,366
+3,392,000
| +6% | +$4.26M |
|
|
ACLX
24
DELISTED
Arcellx
ACLX
| $82.6M | 0.85% |
1,267,156
-1,769,371
| -58% | -$141M |
|
|
CLYM
25
Climb Bio
CLYM
$758M
| $77.7M | 0.8% |
11,293,828
-20,125,439
| -64% | -$48.3M |
|
Similar funds
SCM
AIM
MIF
SIM
NPT
AC
PVI
WPL